Horizon Pharma PLC (NASDAQ:HZNP)‘s stock had its “buy” rating reissued by equities researchers at Mizuho in a research note issued on Wednesday, ARN reports. They currently have a $36.00 price target on the biopharmaceutical company’s stock. Mizuho’s price objective would indicate a potential upside of 93.97% from the company’s previous close.

In other Horizon Pharma PLC news, EVP Jeffrey W. Sherman sold 4,456 shares of the company’s stock in a transaction dated Thursday, December 10th. The shares were sold at an average price of $20.00, for a total transaction of $89,120.00. Following the transaction, the executive vice president now directly owns 105,132 shares in the company, valued at approximately $2,102,640. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Other equities research analysts also recently issued research reports about the stock. Brean Capital restated a “buy” rating and issued a $32.00 target price (up previously from $31.00) on shares of Horizon Pharma PLC in a research note on Monday, December 14th. WallachBeth Capital upgraded shares of Horizon Pharma PLC to a “buy” rating in a research note on Wednesday, November 11th. Stifel Nicolaus restated a “buy” rating on shares of Horizon Pharma PLC in a research note on Wednesday, November 11th. Guggenheim restated a “buy” rating on shares of Horizon Pharma PLC in a research note on Friday, November 6th. Finally, JMP Securities restated a “buy” rating on shares of Horizon Pharma PLC in a research note on Thursday, October 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $33.75.

Horizon Pharma PLC (NASDAQ:HZNP) opened at 18.56 on Wednesday. The firm’s 50-day moving average is $20.07 and its 200 day moving average is $24.31. Horizon Pharma PLC has a 1-year low of $12.86 and a 1-year high of $39.49. The firm’s market cap is $2.96 billion.

Horizon Pharma PLC (NASDAQ:HZNP) last issued its earnings results on Friday, November 6th. The biopharmaceutical company reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.40 by $0.30. The firm earned $292.70 million during the quarter, compared to analyst estimates of $185.70 million. The firm’s revenue for the quarter was up 201.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.24 EPS. On average, equities analysts forecast that Horizon Pharma PLC will post $1.94 earnings per share for the current fiscal year.

A number of hedge funds and institutional investors have added to or reduced their stakes in the stock. Harvest Management acquired a new position in Horizon Pharma PLC during the third quarter worth about $396,000. Essex Investment Management Co. LLC acquired a new position in Horizon Pharma PLC during the fourth quarter worth about $1,625,000. DekaBank Deutsche Girozentrale increased its position in Horizon Pharma PLC by 4.2% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 81,000 shares of the biopharmaceutical company’s stock worth $1,813,000 after buying an additional 3,300 shares during the last quarter. Boston Advisors acquired a new position in Horizon Pharma PLC during the fourth quarter worth about $331,000. Finally, Simplex Trading increased its position in Horizon Pharma PLC by 126.5% in the fourth quarter. Simplex Trading now owns 1,189 shares of the biopharmaceutical company’s stock worth $568,000 after buying an additional 664 shares during the last quarter.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Company’s the United States marketed products are ACTIMMUNE (NASDAQ:HZNP), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

12 Month Chart for NASDAQ:HZNP

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.